Mayfair Advisory Group LLC Has $219,000 Stake in Amgen Inc. (NASDAQ:AMGN)

Mayfair Advisory Group LLC cut its position in Amgen Inc. (NASDAQ:AMGN) by 8.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 842 shares of the medical research company’s stock after selling 80 shares during the quarter. Mayfair Advisory Group LLC’s holdings in Amgen were worth $219,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Capital Performance Advisors LLP acquired a new position in Amgen during the third quarter valued at approximately $25,000. Legacy Investment Solutions LLC bought a new position in shares of Amgen in the 3rd quarter valued at $29,000. Hershey Financial Advisers LLC acquired a new position in shares of Amgen during the 2nd quarter worth $30,000. Matrix Trust Co bought a new stake in shares of Amgen during the 3rd quarter worth $36,000. Finally, Livelsberger Financial Advisory acquired a new stake in Amgen in the third quarter valued at about $56,000. Institutional investors own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Wolfe Research initiated coverage on Amgen in a research note on Friday, November 15th. They set a “peer perform” rating for the company. Piper Sandler dropped their price objective on shares of Amgen from $344.00 to $310.00 and set an “overweight” rating for the company in a research note on Thursday, January 2nd. Royal Bank of Canada decreased their target price on shares of Amgen from $360.00 to $330.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 27th. UBS Group dropped their price target on Amgen from $335.00 to $326.00 and set a “neutral” rating for the company in a research note on Thursday, October 31st. Finally, Redburn Partners reduced their price objective on Amgen from $200.00 to $195.00 in a research report on Wednesday, November 27th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $314.91.

Amgen Trading Down 1.1 %

Shares of AMGN stock opened at $267.10 on Wednesday. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. The stock has a 50 day simple moving average of $277.12 and a two-hundred day simple moving average of $308.03. The company has a market cap of $143.58 billion, a P/E ratio of 34.20, a PEG ratio of 2.91 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, beating the consensus estimate of $5.11 by $0.47. The company had revenue of $8.50 billion during the quarter, compared to analyst estimates of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. Amgen’s revenue for the quarter was up 23.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $4.96 EPS. Research analysts forecast that Amgen Inc. will post 19.53 earnings per share for the current year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be paid a $2.38 dividend. The ex-dividend date is Friday, February 14th. This is an increase from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a dividend yield of 3.56%. Amgen’s dividend payout ratio (DPR) is currently 121.90%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.